Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Rx Compounding Policy Follows 1992 Compliance Guide

Executive Summary

FDA is returning to the drug compounding policy laid out in a 1992 compliance policy guide in response to a recent Supreme Court decision

You may also be interested in...



Pharmacy Compounding: Second Draft Of FDA Compliance Guide Coming Soon

FDA is likely to issue a second draft of its pharmacy compounding compliance policy guide before issuing a final policy

Pharmacy Compounding: Second Draft Of FDA Compliance Guide Coming Soon

FDA is likely to issue a second draft of its pharmacy compounding compliance policy guide before issuing a final policy

Supreme Court Reaffirms Least Restrictive Standard For Ad Controls

The Supreme Court decision overturning restrictions on advertising of compounded drugs suggests that any moves by Congress to control direct-to-consumer advertising will face a close, skeptical review in court

Latest News
See All
UsernamePublicRestriction

Register

PS039968

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel